← All Intellia Therapeutics, INC filings

Intellia Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NTLA
Intellia Therapeutics, INC
10-K: Intellia Therapeutics 2025 Annual Report: HAE Progress Amid ATTR Clinical Hold
Intellia Therapeutics' 2025 annual report highlights significant progress for its HAE program with anticipated 2027 launch, while its ATTR program faces a clinical hold and substantial net losses continue.
NASDAQ
NTLA
Intellia Therapeutics, INC
10-K: Intellia Therapeutics Reports 2024 Results, Advances CRISPR-Based Therapies
Intellia Therapeutics highlights progress in CRISPR-based therapies for ATTR amyloidosis and HAE while reporting its 2024 financial results.
NASDAQ
NTLA
Intellia Therapeutics, INC
10-K: Intellia Therapeutics Reports 2023 Financial Results and Provides Business Update
Intellia Therapeutics, a clinical-stage gene editing company, released its 2023 financial results and provided an update on its business operations, highlighting progress in its CRISPR/Cas9-based therapeutic programs.